Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Solesence Q1 2026 Earnings Call - Gross Margins Expand as Operational Overhaul Drives Near-Term Revenue Miss
Solesence reported a revenue decline to $13 million in Q1 2026, a clear miss driven by On-Time In-Full (OTIF) execution failures during its transition to a new supply chain model. The company’s pivot ...
- Revenue declined 11% year-over-year to $13 million, down from $14.6 million in Q1 2025, primarily due to On-Time In-Full (OTIF) shipment delays rather than a drop in customer demand.
- Gross margin expanded by 300 basis points to 26%, driven by improved labor efficiency and the elimination of product quality-related waste that plagued the prior year.
- Net income swung to a $0.8 million loss from a $0.08 million profit in the prior year, reflecting near-term investments in operational infrastructure and organizational realignment.
- +9 more takeaways
Pattern Q1 2026 Earnings Call - Record 127% Net Revenue Retention Drives Raised Guidance
Pattern delivered a record first quarter for 2026, with revenue surging 43% year-over-year to $774 million and adjusted EBITDA climbing 59% to $54 million. The company raised its full-year revenue out...
- Revenue grew 43% year-over-year to $774 million in Q1 2026, exceeding prior expectations and validating the company’s growth trajectory.
- Adjusted EBITDA reached $54 million, up 59% year-over-year, driven by revenue expansion and operating leverage across sales, marketing, and operations.
- Net revenue retention (NRR) hit a record 127%, up from 115% in the prior year, reflecting strong existing brand partner growth and platform stickiness.
- +7 more takeaways
Novo Nordisk Q1 2026 Earnings Call - Wegovy Pill Uptake Offsets Price Erosion
Novo Nordisk’s Q1 2026 results reveal a company navigating a complex pricing environment while accelerating its commercial momentum. Adjusted sales fell 4% due to lower realized prices, but volume gro...
- Adjusted sales declined 4% due to lower realized prices, partially offset by GLP-1 volume growth and market expansion.
- Wegovy pill achieved record-breaking uptake, exceeding 1 million patients in just 16 weeks post-launch in the U.S.
- The Wegovy franchise now holds approximately 65% new-to-brand (NBRX) market share in the U.S. anti-obesity medication space.
- +7 more takeaways
Bioceres Crop Solutions Q3 FY2026 Earnings Call - ProFarm Foreclosure and Litigation Dominate Financials
Bioceres Crop Solutions faced a turbulent fiscal third quarter, overshadowed by the foreclosure of its ProFarm business and ongoing litigation with secured note holders. The company reported a net los...
- Total revenues declined 23% year-over-year to $39.4 million, with Crop Protection down 18% and Seed/Integrated Products down 71% due to strategic phasing out of low-margin seed sales.
- Crop Nutrition was the sole growth segment, rising 15% year-over-year to $11.6 million, driven by strong demand for microbial fertilizers amid global supply uncertainties.
- Gross profit fell 30% to $12.7 million, with a 38% decline in Crop Nutrition primarily due to a non-recurring inoculant obsolescence adjustment.
- +7 more takeaways
AECOM Q2 2026 Earnings Call - Record Backlog and Raised Guidance Driven by AI Wins and Defense Spending
AECOM delivered a second quarter of record-breaking execution, pushing adjusted EBITDA and adjusted EPS to new highs while expanding its backlog to an all-time level. The company raised full-year guid...
- Full-year adjusted EPS and EBITDA guidance raised to 14% and 7% growth respectively, marking the second upward revision this year.
- Record backlog reached new highs, driven by a 1.2x design book-to-burn ratio and robust win rates across the Americas and International segments.
- Americas design business drove 8% net service revenue growth, with segment adjusted operating margins expanding 60 basis points to 20%.
- +7 more takeaways
Biote Corp Q1 2026 Earnings Call - Supply Recall Drags Results as Management Bets on H2 Recovery
Biote Corp reported a sharp drop in first-quarter revenue and earnings, primarily due to a voluntary recall of bioidentical hormone pellets that cost the company $1.7 million in lost revenue and $1.5 ...
- Revenue fell 8.3% year-over-year to $44.9 million, with procedure revenue declining 13.2% to $31.3 million due to the voluntary product recall.
- The recall resulted in an estimated $1.7 million revenue impact and approximately $1.5 million in incremental costs, severely impacting Q1 gross margin which dropped to 68.9% from 74.3%.
- Net income was $2.7 million ($0.06 per diluted share), a significant decrease from $15.8 million ($0.37 per diluted share) in Q1 2025, partly due to smaller fair value gains on earn-out liabilities.
- +7 more takeaways
Legend Biotech Q1 2026 Earnings Call - CARVYKTI Sales Surge 62% as In Vivo Pipeline Gains Traction
Legend Biotech delivered a quarter of clear commercial momentum in Q1 2026, with CARVYKTI net trade sales reaching $597 million, up 62% year-over-year. The growth was broad-based, fueled by rapid expa...
- CARVYKTI net trade sales reached $597 million in Q1 2026, representing 62% year-over-year growth.
- U.S. sales grew 36% year-over-year, while ex-U.S. sales surged more than 200% year-over-year.
- Nearly 80% of CARVYKTI patients are treated in the community setting, with 41% of U.S. apheresis volume now in second and third lines.
- +7 more takeaways
Alliance Laundry Systems Q1 2026 Earnings Call - Raised Full-Year Guidance on Broad-Based Growth and Tariff Resilience
Alliance Laundry Systems delivered a robust first quarter of 2026, with revenue rising 10% year-over-year to $427 million and adjusted EBITDA climbing 9% to $109 million. The company raised its full-y...
- Revenue grew 10% year-over-year to $427 million, driven by 3% real unit volume growth and pricing actions.
- Adjusted EBITDA increased 9% to $109 million, with an adjusted EBITDA margin of 25.5%.
- Adjusted net income surged 85% year-over-year to $63 million, reflecting improved operating performance and lower interest expenses.
- +7 more takeaways
Arcutis Biotherapeutics Q1 2026 Earnings Call - ZORYVE Sales Surge 65% as Cash Flow Turns Positive
Arcutis Biotherapeutics delivered a robust first quarter in 2026, with ZORYVE net product revenues climbing 65% year-over-year to $105.4 million. The growth came despite heavy first seasonality, a pul...
- ZORYVE net product revenues reached $105.4 million in Q1 2026, a 65% increase year-over-year, driven by strong patient demand and improved gross-to-net from better formulary positioning.
- Arcutis achieved positive operating cash flow for the second consecutive quarter, generating $2.2 million in net cash from operations, a rare milestone for a growth-stage biotech.
- The company submitted a supplemental NDA to the FDA for ZORYVE cream 0.05% in infants aged 3 to 24 months with atopic dermatitis, based on rapid efficacy and safety data from the INTEGUMENT-INFANT trial.
- +7 more takeaways
Pangaea Logistics Solutions Q1 2026 Earnings Call - TCE Premiums and Chartered-In Fleet Expansion Drive Stronger Profitability
Pangaea Logistics Solutions delivered a solid Q1 2026, with adjusted EBITDA up $10M YoY to $25.2M, driven by TCE rates averaging 20% above market indices and a 14% increase in shipping days. The compa...
- Adjusted EBITDA grew $10M YoY to $25.2M, driven by 34% increase in TCE earnings.
- TCE rates averaged $15,252/day, a 20% premium over market indices for Panamax, Supramax, and Handysize vessels.
- Chartered-in fleet increased 54% YoY, allowing Pangaea to capture market opportunities without compromising flexibility.
- +7 more takeaways